Objective To assess pregnancy and birth outcomes in infants born to women who did or did not receive tetanus, diphtheria, acellular pertussis (Tdap) vaccine during pregnancy. Results From 162 448 pregnancies we identified 138 women (0.08%) with documented Tdap administration during pregnancy (cases); 552 pregnant women without documented Tdap were randomly selected as controls. Of 138 immunized women, 63% received Tdap in the first trimester and 37% after. Tdap was given most commonly as wound prophylaxis. The incidence of spontaneous or elective abortion was no greater in Tdap cases than in controls. There were no significant differences in preterm delivery, gestational age, or birth weight between groups. One or more congenital anomaly was identified in 3.7% (95% CI 1.2%-8.5%) of case infants and 4.4% (95% CI 2.7%-6.5%) of control infants (P = .749). In infants born to women receiving Tdap during pregnancy, 3.6% (0.8%-10.2%) had International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses consistent with complex chronic conditions within 12 months compared with 10.4% (95% CI 7.2%-14.4%) of infants of controls (P = .054).
Results From 162 448 pregnancies we identified 138 women (0.08%) with documented Tdap administration during pregnancy (cases); 552 pregnant women without documented Tdap were randomly selected as controls. Of 138 immunized women, 63% received Tdap in the first trimester and 37% after. Tdap was given most commonly as wound prophylaxis. The incidence of spontaneous or elective abortion was no greater in Tdap cases than in controls. There were no significant differences in preterm delivery, gestational age, or birth weight between groups. One or more congenital anomaly was identified in 3.7% (95% CI 1.2%-8.5%) of case infants and 4.4% (95% CI 2.7%-6.5%) of control infants (P = .749). In infants born to women receiving Tdap during pregnancy, 3.6% (0.8%-10.2%) had International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses consistent with complex chronic conditions within 12 months compared with 10.4% (95% CI 7.2%-14.4%) of infants of controls (P = .054).
Conclusions Documented Tdap administration during pregnancy was uncommon and occurred most often in the first trimester as prophylaxis following trauma. No increase in adverse outcomes was identified in infants born to women receiving Tdap compared with infants of controls. (J Pediatr 2013;163:1422-26).
P ertussis is an endemic vaccine-preventable disease with the highest morbidity and mortality in the youngest infants. [1] [2] [3] [4] [5] [6] In 2012, increased pertussis activity was reported in 49 states. 7 In the US, the primary pertussis immunization series is not completed until 6 months of age, leaving young infants vulnerable to pertussis. Of pertussis-related deaths reported to the US Centers for Disease Control from 2000-2006, 93% were in infants younger than 12 months. 2 Several studies have confirmed the potential to provide protection from pertussis in newborns through passive transfer of maternal antibody during pregnancy. [8] [9] [10] [11] [12] [13] In an effort to reduce the burden of pertussis disease in young infants, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) approved recommendations for the use of tetanus, diphtheria, acellular pertussis (Tdap) vaccine after 20 weeks gestation in previously unimmunized pregnant women in June 2011. 1 These recommendations were endorsed by the American College of Obstetricians and Gynecologists. 14 In October 2012, ACIP recommended expansion of Tdap guidelines to include every pregnant woman during every pregnancy irrespective of previous history of Tdap immunization and optimally at between 27 and 36 weeks gestation to maximize passive antibody transfer to the infant. 15 Few studies have examined pregnancy or infant outcomes for women receiving Tdap during pregnancy. A 2012 Vaccine Adverse Event Reporting System study of 132 pregnant women who received Tdap described no adverse event in 42%, spontaneous abortion in 16.7%, and 1 major congenital anomaly. 16 Among 518 prospective reports to the Adacel (Tdap) Pregnancy Registry from June 2005 through June 2011 with known pregnancy outcomes, the rate of spontaneous abortion was 12.6% and elective abortion was 1.6%; loss to follow-up for the registry was 67%. 17 Interpretation of passive surveillance data, particularly during pregnancy, is complex given the potential bias associated with reporting adverse events and the inability to determine a true adverse event rate.
We recognized an opportunity to use the electronic medical records of Intermountain Healthcare to (1) identify women who received Tdap during pregnancy (cases) and determine when and why administration occurred; (2) assess pregnancy and infant health outcomes in women who received Tdap during pregnancy compared with pregnant women without documentation of Tdap immunization during pregnancy (controls); and (3) identify the prevalence of complex chronic conditions in the first 12 months in infants born to cases compared with infants born to controls.
Methods
Approval to conduct this study was granted by the Institutional Review Boards of the University of Utah and Intermountain Healthcare in Salt Lake City, Utah. Waiver of informed consent was granted by both institutions.
Intermountain Healthcare is the largest vertically integrated system of health care facilities in Intermountain Healthcare West with more than 30 000 deliveries each year. All Intermountain Healthcare facilities share a single electronic medical record that captures vaccine administration. Data are stored in the Intermountain Healthcare Enterprise Data Warehouse (EDW). To retrospectively identify Tdap administration during pregnancies occurring from May 1, 2005, through August 31, 2009, we created a pregnancy episode table that included all women who had at least 1 International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code associated with pregnancy. During these years, Tdap was not recommended for pregnant women.
Pregnancy outcomes included spontaneous or elective abortions, stillbirths and live births, and a standard hierarchy was established to identify pregnancy start and end dates (Appendix; available at www.jpeds.com). The Intermountain Healthcare EDW was queried to identify all pregnant women with documented receipt of Tdap immunization within 280 days (40 weeks) of the pregnancy end date. Women who had documentation of Tdap vaccine within 3 days prior to the delivery outcome were excluded due to the likelihood that these encounters represented postpartum Tdap immunization. Four pregnant women without documentation of Tdap immunization were randomly identified from the Intermountain Healthcare EDW to serve as controls for each case. The electronic medical records for infants born to each case and control were identified and linked to maternal records.
The Intermountain Healthcare EDW database query ascertained pregnancy outcomes, including preterm (<37 weeks gestation) or term ($37 weeks gestation) delivery, delivery of a live-born infant, stillbirth, spontaneous abortion, or elective abortion for all cases and controls in our cohort. The following data also was obtained for each maternal case: trimester of immunization, immunization date, and the type of encounter in which Tdap was administered (eg, acute care or health supervision). For infants, the following outcomes at time of delivery were identified: gestational age, birth weight, and the presence of ICD-9-CM diagnosis codes for congenital malformations or adverse perinatal events. Complex chronic conditions for infants who had at least 1 additional medical encounter at an Intermountain Healthcare facility during the first 12 months after delivery were identified and categorized using both inpatient and outpatient ICD-9-CM diagnosis codes as previously defined by Feudtner et al 18 
Statistical Analyses
Data were analyzed using Stata v. 12.1 (StataCorp, College Station, Texas). Descriptive statistics were used to characterize the proportion of women who received Tdap during pregnancy and reason for visit at the time of immunization by ICD-9-CM diagnosis. The independent sample t test was used to compare cases and controls and their infants by maternal age, gestational age, and birth weight after evaluating distributions for normality. Prematurity, congenital anomalies, and the presence of complex chronic conditions in infants born to cases and controls were compared by c 2 test and 95% CIs were calculated around the point estimates.
Results
There were 162 448 pregnancies during the study period. We identified 138 (0.08%) women with documented Tdap during a pregnancy episode; 552 pregnancies in which there was no documentation of Tdap were randomly chosen for comparison of pregnancy and birth outcomes. The mean age of pregnant women was 27 years for both cases (range = 14-40) and controls (range = 14-43) (P = .735).
Visit Type and Trimester of Tdap Administration
Based on ICD-9-CM diagnosis codes, the primary reason and trimester at the visit Tdap administration occurred are shown in the Figure. The most common reasons women received Tdap were prophylaxis for open wounds or during acute care visits for trauma (47%) and routine health supervision (46%). Of the 138 immunized women, 87 (63%) received Tdap in the first trimester, 24 (17%) in the second, and 27 (20%) in the third.
Pregnancy and Infant Outcomes in Cases and Controls
Of the 138 women who received Tdap during a pregnancy, 4/138 (2.9%; 95% CI 0.9%-7.7%) had spontaneous or elective abortions compared with 49/552 (8.9%; 95% CI 6.7%-11.6%) of controls (P = .019). Even though no pregnancy in cases resulted in stillbirth, 5 (0.9%) control pregnancies resulted in a stillborn infant. Preterm delivery (<37 weeks) occurred in 8/134 (6.0%; 95% CI 2.8%-11.8%) of live born infants born to cases compared with 38/505 (7.5%; 95% CI 5.4%-10.3%) of infants born to controls (P =.536).
Mean gestational age for infants was 39 weeks for both cases (range = 29-41) and controls (range = 28-42) (P = .578). Mean birth weight for infants born to immunized women was 3384 g compared with 3305 g for infants born to controls (P = .116).
At birth, ICD-9-CM codes for congenital anomalies were present in 5/134 (3.7%; 95% CI 1.2%-8.5%) of infants Vol. 163, No. 5 November 2013 born to cases and 4.4% (22/505) (95% CI 2.7%-6.5%) of infants born to controls (P = .749; Table) . By 12 months of age, 62% (83/134) of infants born to women who had received Tdap and 61% (307/505) of infants born to controls had at least 1 additional health encounter at an Intermountain Healthcare facility. Of these infants, 3/83 (3.6%; 95% CI 0.8%-10.2%) born to cases had at least one ICD-9-CM diagnosis consistent with a complex chronic condition vs 32/307 (10.4%; 95% CI 7.2%-14.4%) of infants born to controls (P = .054; Table) .
No infant in either group had an ICD-9-CM diagnosis code for pertussis in the year following birth.
Discussion
This retrospective study reports a large cohort of pregnant women immunized with Tdap during pregnancy. Although a small proportion of pregnant women overall (<0.1%) received Tdap immunization, we identified 138 women with documented Tdap during pregnancy. Pregnant women in our cohort most commonly received Tdap during acute care visits for wound prophylaxis during the first trimester of pregnancy, when the health care provider and the woman herself may have been unaware of the pregnancy. Our shared electronic medical record allowed us to capture multiple health encounters for mother-infant pairs that allowed us to identify ICD-9-CM diagnoses in infants born to cases and controls, congenital anomalies at birth, and complex conditions apparent by 12 months of age. Pregnancy outcomes for immunized women, the majority of whom were immunized in the first trimester, were good and similar to controls. Further, infants of cases were no more likely to be preterm, to be diagnosed with congenital malformations at birth, or to have complex chronic conditions diagnosed in the first year than infants of controls.
Tdap vaccine administration in this cohort of pregnant women was uncommon. Given that Tdap immunization during pregnancy was not yet recommended in any trimester of pregnancy during the study period, our finding of infrequent Tdap administration is not surprising. Routine immunization of pregnant women with the intent to provide transplacental protection to newborns from pertussis is now recommended by both ACIP and American College of Obstetricians and Gynecologists. 14, 15 Although the current recommendations are for immunization between 27 and 36 weeks gestation, our data provide reassurance that pertussis immunization, even during the first trimester, is not associated with increases in the adverse events measured.
Many pregnant women in our study who received Tdap were immunized in the first trimester during acute care visits for a laceration repair or trauma. A significant proportion of immunized women also received Tdap vaccine early in pregnancy as part of a routine health supervision visit. It is likely that most healthcare providers, and perhaps the women themselves, were unaware of the pregnancy during the (1) Cardiovascular (14) Gastrointestinal (1) Respiratory (6) Renal (4) Gastrointestinal (1) Metabolic (5) Genetic (6) Malignancy (1) THE JOURNAL OF PEDIATRICS www.jpeds.com
Vol. 163, No. 5 immunization encounter. Many pregnant women likely have received Tdap for valid medical indications even before the new recommendations for administration of Tdap during every pregnancy. Our study demonstrates that women immunized during pregnancy and their infants were no more likely to experience adverse events than concurrent control mother-infant pairs in our population. In our cohort, 2.9% of women with documented Tdap during pregnancy had a spontaneous or elective abortion, 6.0% delivered preterm infants, and no pregnancy in this group resulted in stillbirth. A study conducted by Black et 20 In women in our cohort with documented Tdap during pregnancy, rates of abortion, preterm delivery, and stillbirth were all lower than previously reported background rates. The rates of spontaneous abortion and preterm delivery among controls were slightly lower than those reported by Black et al. This may reflect differences in the population studied and the methods of ascertainment. The comparison of our findings and these studies demonstrate the complementary role of concurrently controlled studies and comparing background incidence of adverse outcomes when evaluating adverse events during pregnancy.
One of the strengths of our study is the unbiased detection of all women with documented Tdap administration in a large cohort of pregnant women and comparison with a concurrent control group drawn from the same population. Previous published data available on pregnancy outcomes in women receiving Tdap vaccine use passive surveillance that is subject to a number of potential biases including the increased likelihood of reporting adverse pregnancy outcomes. Another strength of this study is our ability to report on the more long-term outcomes in infants born to women receiving Tdap during the pregnancy. The robust electronic data available in the Intermountain Healthcare EDW also allowed us to track infant health encounters using ICD-9-CM codes during the first 12 months after delivery and we were able to capture data for a significant proportion of infants born to both cases and controls. Infants born to cases who received further care within the Intermountain Healthcare system were no more likely to be diagnosed with complex chronic conditions in the first year than infants born to controls. Although many chronic medical conditions are not related to in utero infection, these codes are likely to detect congenital anomalies or birth defects that are diagnosed after the postpartum period.
Our study has several limitations. Tdap administration was uncommon and our cohort was small. However, although only 138 cases were identified, this represents one of the largest cohorts of pregnant women receiving Tdap reported in the medical literature and includes many women immunized during the first trimester. It is also possible that miscoding in pregnancy and birth outcomes may have occurred, and other factors such as parity, previous pregnancy loss, and family history of congenital conditions could have affected the study findings. However, we rigorously reviewed outcomes, and we are satisfied that all pertinent outcomes are accurately represented. Finally, our data were observational and collected retrospectively. We, therefore, cannot accurately speculate on the reason for fewer spontaneous or elective abortions in cases compared with controls. This pregnancy outcome may be due to the small number of cases or to unmeasured factors. However, the absence of increased adverse outcomes in cases and their infants through 12 months of age provides further evidence to support the current recommendations for Tdap immunization in pregnant women.
The results of this retrospective study are encouraging. However, prospective trials will be required to confirm the safety and efficacy of Tdap immunization during pregnancy. Two trials are underway in the US and Canada to assess the safety of Tdap during pregnancy. 21, 22 Both trials have recruited small cohorts of healthy women in the third trimester (30-32 weeks) of pregnancy to further evaluate safety and immunogenicity of Tdap immunization in the mother and diphtheria, tetanus, acellular pertussis immunization in the infant. 21, 22 The new universal recommendations for immunization of pregnant women during second and third trimester will afford further opportunity to collect prospective safety data on large cohorts of women. n 
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